Image Sourced ShutterStock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • MedAdvisor and Zuellig Pharma have signed the first customer for MedExpress Drugstores
  • The company will provide digital medication platforms to more than 1.5 million customers across the Philippines

MedAdvisor Limited, and its 50:50 joint venture with Zuellig Pharma, has signed its first customer, MedExpress Drugstores.

Serving 1.5 million customers and 50 hospitals nationwide MedExpress is the leading delivery and hospital outpatient pharmacy chain in the Philippines.

This agreement is for Zuellig to provide digital programs to its customers via SMS as well as a ‘MedExpress’ mobile medication management app. This app will help customers track their medication and refills from MedExpress.

Fill-My-Scripts automatically reminds patients when to refill their recurring scripts and chases them up if they forget. MedAdvisor will send a message providing information if the medication is running low.

The automated message will only send these messages if the script hasn’t been filled out five days before the medication runs out. If the scripts are up to date MedAdvisor will remind on the day and again when the patient has been without medication for three days.

With Tap-To-Refill patients can order prescriptions online so they are ready to collect at a pharmacy without any waiting times. Repeat prescriptions can be preordered and dispensed at a local pharmacy for pickup.

Take-My-Meds reminds patients when to take specific medications each day and at the appropriate time. This feature alerts their phone every time medication is due to be taken and the notifications include details of exactly which medications are due at which time.

The agreement is set for an initial 18 month period beginning from when that app is available and can be renewed for further 24 month extensions after.

Please find announcement here  

MDR by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Unith wraps up Q1 with $5M in cash as digital humans evolve

Unith has wrapped up Q1 of 2024 with nearly $5M in cash and opex reduced. But…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…